82 results about "Serum biomarkers" patented technology

Certain biomarkers and biomarker combinations are useful in a qualifying lung cancer status in a subject. A diagnostic methodology employing these biomarkers and combinations can detect whether a subject has lung cancer.

Certain biomarkers and biomarker combinations are useful in a qualifying hepatocellular carcinoma status in a patient. A diagnostic methodology employing these biomarkers and combinations can distinguish between hepatocellular carcinoma and chronic liver disease, for example.

The present invention concerns the identification and detection of maternal serum biomarkers of pre-eclampsia and associated complications, gestational hypertension and placental insufficiency using global proteomic approaches. The invention further concerns the identification of maternal serum biomarkers for detection of pre-eclampsia and associated complications, gestational hypertension and placental insufficiency during early gestation.

Certain biomarkers and biomarker combinations are useful in a qualifying ischaemic heart disease status in a patient. A diagnostic methodology employing these biomarkers and combinations can distinguish between ischaemic heart disease and normal, as well as between cases of severe myocardial infarction versus mild myocardial infarction.

The invention provides a preparation method and application of a magnetic MIL-100 composite material. The magnetic MIL-100 composite material is Fe3O4/C@MIL-100, wherein the MIL-100 is a metal-organic framework material constructed by iron and trimesic acid. A synthesis method comprises the following steps: firstly, preparing a carbon layer clad magnetic microsphere and preparing the Fe3O4/C@MIL-100 composite material. The prepared magnetic MIL-100 composite material is used for finding and detecting a blood serum biomarker. The preparation method and the application, provided by the invention, have the advantages that a carbon layer is ingeniously and uniformly clad on the surface of a high-quality Fe3O4 microsphere by the preparation method, and the Fe3O4/C@MIL-100 composite material is prepared in situ by a one-pot method; the composite material has a magnetic separation property of magnetic nano particles and a size exclusion effect of MIL-101; and high-abundant protein does not need to be removed, and the composite material can be rapidly and efficiently suitable for finding and detecting the blood serum biomarker.

The invention relates to the field of the biological science, in particular to a diagnostic kit and an application of coiled-coil domain containing protein 49 (CCDC49) in preparing a gastric cancer early-stage diagnostic reagent. The diagnostic kit is used for diagnosing the early-stage gastric cancer. The diagnostic kit comprises an elisa plate, human protein CCDC49, standard serum, an enzyme labeled reagent, enzyme substrate solution, confining liquid, sample diluent, detergent liquid and termination liquid, wherein the human protein CCDC49 is wrapped on the elisa plate. Compared with the prior art, the diagnostic kit has advantages that 1, a commodity diagnostic kit which is sensitive, safe, reliable and easy to operate is provided, the immunoglobulin m (IgM) antibody for resisting the protein CCDC49 in the human serum can be qualitatively determined, and the early diagnosis of the gastric cancer can be assisted; and 2, the specificity of the provided serum biological labeled protein CCDC49 is 81 percent, the sensitivity is 82 percent, and the characteristics of high specificity and high sensitivity can be realized.

Presented herein are novel blood plasma/serum biomarkers related to cardiovascular disease. These newly identified biomarkers create the basis for multiple (single) assays using traditional bioassay technologies and when used in combination yield exceptional clinical sensitivity and specificity in the determination of myocardial infarction (MI). A multiplexed, mass spectrometric immunoassay (MSIA) able to simultaneously assay for the new/novel biomarkers as well other MI markers is also presented. Means and methods for evaluating data generated using multiple biomarkers in order to validate findings and further the use of the multiplexed MI assay in clinical, diagnostic and therapeuatic uses is also included.

The invention discloses application of an RBP4 as a colorectal cancer blood serum marker and a diagnostic kit, and belongs to the technical field of biology. On one hand, the invention provides the technical scheme of the application of the RBP4 as the colorectal cancer blood serum marker, and on the other hand, the invention provides the technical scheme of the colorectal cancer diagnostic kit. The advantages that the blood serum biological marker has the specificity of 81.7% and the sensibility of 74.9% and has high specificity and sensibility, a flexible, reliable and operable method is provided, the antigen level of the RBP4 in human blood serum is quantitatively measured and the RBP4 can easily assist in colorectal cancer early diagnosis are achieved.

The invention relates to a biomarker, and particularly relates to a serum miRNA biomarker composition and an application thereof. The serum miRNA biomarker composition comprises at least one miRNA and sequences of reverse transcription primers, forward primers and reverse primers of all miRNAs. The serum miRNA biomarker composition can be used for preparing oligozoospermia and azoospermia detection reagents. An oligozoospermia and azoospermia detection kit comprises the serum miRNA biomarker composition, Taq enzyme, dNTP, MgCl2 and a PCR buffer solution. The serum miRNA biomarker composition provided by the invention has the advantages of high sensitivity, low sample consumption, wide detection range and wide linear quantitative range.

The invention belongs to the technical field of biomedical detection, particularly relates to a lung cancer marker anti-ACTR3 autoantibody and applications thereof, and discloses a lung cancer marker,which is an anti-ACTR3 autoantibody. The invention further provides applications of the lung cancer marker in preparation of lung cancer detection kits. According to the present invention, the serumbiomarker with characteristics of simple operation, low cost, high accuracy and non-invasive application in clinic is provided; the research results show that the detection of the serum anti-ACTR3 autoantibody with the ELISA method can accurately distinguish lung cancer patients from normal people and patients with benign lung diseases, and can be used for early detection of lung cancer; and in the context, the marker for conveniently, rapidly and effectively detecting lung cancer patients and the lung cancer detection kit prepared by using the marker can be used for clinical early diagnosis of lung cancer.

The invention relates to the field of bioscience, in particular to a diagnostic kit and application of an RNF19 (ring finger protein 19) in preparation of a reagent for early diagnosis of gastric cancers. The diagnostic kit is used for early diagnosis of gastric cancers and comprises an ELISA (enzyme-linked immunosorbent assay) plate, a human protein RNF19, standard serums, an ELISA reagent, an enzyme substrate solution, confining liquid, sample diluent, washing liquid and stop liquid, wherein the human protein RNF19 is enveloped on the ELISA plate. Compared with the prior art, the diagnostic kit has the following advantages: 1. a sensitive, safe, reliable and easy-to-operate commercial kit is provided, is used for qualitatively determining the level of the IgA antibody against RNF19 in the human serums, and is conductive to early diagnosis of gastric cancers in an aided manner; and 2. the provided serum biomarker RNF19 has specificity of 86% and sensitivity of 86% and has the characteristics of high specificity and high sensitivity.

The invention discloses an application of a karyosome protein SP110 and a kit containing the karyosome protein SP110 to the preparation of an early diagnosis reagent for alcoholic cardiomyopathy (ACM). Found by analyzing related blood serum of a patient suffering from the ACM by virtue of the advantages of high throughput and high analysis speed of a human proteome chip and comparing the differences of samples of the patient suffering from the ACM, a patient suffering from dilated cardiomyopathy (DCM) and a healthy person within relatively short time, the expression level of the karyosome protein SP110 in the patient suffering from the ACM is obviously higher than that of each of the patient suffering from the DCM and the healthy person, which hints that the karyosome protein SP110 can beused as a candidate blood serum biomarker of the ACM to realize early diagnosis of the ACM. Experiments prove that the blood serum marker SP110 provided by the invention has the specificity of 80% andthe sensibility of 82% and has the characteristics of high specificity and high sensibility. Further, the invention provides a commercial kit which is sensitive, safe, reliable and easy to operate, and the commercial kit can be used for qualitatively testing the level of IgM antibodies resisting to SP110 in the human blood serum and is beneficial to the early diagnosis of the ACM.

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Chagas disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with Chagas disease or non-infected. The biomarkers can be detected by SELDI mass spectrometry.

The invention discloses a serum biomarker for early diagnosis of schistosomiasis japonica. The serum biomarker is phosphatidylcholine and/or palmitoyl choline. The sensitivity and specificity of the marker are both greater than 0.9, and the under-curve area (AUC) is greater than 0.9, which indicates that the two indexes have favorable predictability and can be used for early diagnosis of schistosomiasis japonicum katsurada. The invention further discloses a screening method of the serum biomarker for early diagnosis of schistosomiasis japonica based on metabonomics. A mouse schistosomiasis japonica model is constructed, and the metabonomics analysis is carried out on mouse serum by utilizing an ultra-high performance liquid chromatography-tandem mass spectrometry technology, and characteristic differential metabolites between a normal mouse and a schistosomiasis japonica infected mouse are found and analyzed, namely, the schistosomiasis japonica early diagnosis biomarker is obtained. The screening method has the characteristics of convenience and quickness, can accurately reflect the metabolic spectrum difference between a schistosomiasis japonicum infected mouse and a normal mouse, and is high in specificity.

The invention discloses a group of serum metabolite micromolecule markers related to the diagnosis of ischemic stroke complicated with stress ulcer. The biomarkers include one or more of glycine, phenylalanine, ornithine, palmitoleic acid, arachidonic acid, and oleic acid. The analysis and detection method based on the biomarker group has advantages of high sensitivity, high throughput and simpleoperation; the accurate diagnosis of ischemic stroke complicated with stress ulcer can be realized; and a diagnostic reagent for the ischemic stroke complicated with stress ulcer can be prepared.

The invention relates to a method for detecting a serum biomarker of a liver cancer patient. Alpha fetoprotein is closely related to generation and development of various tumors, is mainly used as a serum marker of liver cancer clinically, and is used for diagnosis and curative effect monitoring of primary liver cancer. Therefore, the high-sensitivity detection of the alpha fetoprotein is of greatsignificance to the early diagnosis and treatment of liver cancer patients. The invention provides a method for detecting alpha fetoprotein in human serum by using a novel signal controlled-release nano material for enzyme-free immunoassay based on alpha fetoprotein and primary and secondary antibodies thereof. The method not only overcomes the difficulties that the traditional method depends onperoxidase to generate signals and amplify the signals, but also remarkably improves the detection sensitivity, simplifies the detection process, reduces the cost, widens the application field, and solves the problems of complex enzyme-linked immunosorbent assay technology, high price, insufficient sensitivity and the like; the method has a wide application prospect in the fields of early diagnosis and treatment of tumors and the like, and a novel method with high sensitivity and high specificity is provided for enzyme-free immunodetection.

The invention discloses a pulmonary nodule auxiliary diagnosis method based on a three-dimensional multi-resolution attention capsule network, and belongs to the technical field of medical image processing. The method comprises the following steps: obtaining a pulmonary nodule CT image data set containing a pathological type label; preprocessing samples in the data set; constructing a three-dimensional multi-resolution attention capsule network; and inputting the preprocessed data sample into the three-dimensional multi-resolution attention capsule network for training, and improving the prediction capability of the three-dimensional multi-resolution attention capsule network on multiple pathological types of pulmonary nodules by learning sample distribution. According to the method of the invention, manual features do not need to be designed or auxiliary information such as serum biomarkers does not need to be utilized, and high prediction precision and high robustness can still be kept for small samples difficult to classify and unbalanced and multi-label clinical data sets.